360
Participants
Start Date
May 9, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Avelumab
This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
Yamagata University Hospital, Yamagata
Hirosaki University Hospital, Hirosaki
Ehime University Hospital, Tōon
Kurume University Hospital, Kurume
Hokkaido University Hospital, Sapporo
Sapporo Medical University Hospital, Sapporo
Kobe University Hospital, Kobe
Iwate Medical University Hospital, Shiwa-gun
Kagawa University Hospital, Kita-gun
St. Marianna University Hospital, Kawasaki
Kitasato University Hospital, Sagamihara
Nara Medical University Hospital, Kashihara
Kindai University Hospital, Sayama
Saitama Medical University International Medical Center, Hidaka
Juntendo University Hospital, Bunkyō City
Nippon Medical School Hospital, Bunkyo-ku
National Cancer Center Hospital, Chuo-ku
Teikyo University Hospital, Itabashi-ku
Akita University Hospital, Akita
Kyushu Cancer Center, Fukuoka
Kumamoto University Hospital, Kumamoto
University Hospital Kyoto Prefectural University of Medicine, Kyoto
Kyoto University Hospital, Kyoto
Osaka International Cancer Institute, Osaka
Tokushima University Hospital, Tokushima
Toyama University Hospital, Toyama
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY